A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerative Colitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Etrasimod (Primary)
  • Indications Ulcerative colitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 10 Nov 2017 Status changed from recruiting to active, no longer recruiting, as reported in an Arena Pharmaceuticals media release.
    • 07 Nov 2017 According to an Arena Pharmaceuticals media release, the company expects to complete enrollment in this trial during this week (2nd week of November 2017) and expects data in the first quarter of 2018.
    • 06 Sep 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top